Takeda Signs a Licensing Agreement with Curadev for Stimulator of Interferon Genes (STING) Agonist

 Takeda Signs a Licensing Agreement with Curadev for Stimulator of Interferon Genes (STING) Agonist

Takeda Signs a Licensing Agreement with Curadev for Stimulator of Interferon Genes (STING) Agonist

Shots:

  • Takeda enters into a licensing agreement with Curadev for its Stimulator of Interferon Genes (STING) agonist/ CRD5500 and its associated patents
  • The focus of the agreement is to develop immuno-oncology targets, providing one day deliver transformational benefit to patients. Additionally, out-licenses its IP portfolio to Endo, Medivation & Roche
  • Curadev’s CRD5500 is a sting agonist amenable to bioconjugation as an ADC targeting anti-PD-L1/anti-CTLA4/IDO-TDOi, activating human STING variants to shrink tumors and successfully conjugated with trastuzumab

Click here to read full press release/ article | Ref: PRNewsWire | Image: Twitter


Tuba Khan

Tuba Khan is an Editor and Digital Marketing expert at PharmaShots. She is curious, creative, and passionate about recent updates and innovation in Lifesciences industry. She covers Pharma, Medical devices, Diagnostics and Digital health segment. Tuba also has an experience of digital and social media marketing and can run the campaign independently. She is also certified as a Digital marketer and social media marketer. She can be contacted on tuba@pharmashots.com

Related post